9/26/2013

PATH, an international nonprofit organization, has been granted rights through a deal with Janssen R&D of Ireland to develop an injectable form of the HIV-1 drug rilpivirine as a potential preventive treatment for HIV. Backed by the Bill & Melinda Gates Foundation, PATH plans to carry out prophylaxis trials in partnership with the HIV Prevention Trials Network and the NIH's AIDS division. PATH and Janssen could enter a late-stage development deal based on the results of the trial.

Related Summaries